Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
680.72B
Market cap680.72B
Price-Earnings ratio
43.35
Price-Earnings ratio43.35
Dividend yield
1.85%
Dividend yield1.85%
Average volume
7.77M
Average volume7.77M
High today
$290.40
High today$290.40
Low today
$282.33
Low today$282.33
Open price
$288.98
Open price$288.98
Volume
7.94M
Volume7.94M
52 Week high
$290.40
52 Week high$290.40
52 Week low
$193.55
52 Week low$193.55

Stock Snapshot

With a market cap of 680.72B, Johnson & Johnson(JNJ) trades at $282.91. The stock has a price-to-earnings ratio of 43.35 and currently yields dividends of 1.85%.

On 2026-11-16, Johnson & Johnson(JNJ) stock traded between a low of $282.33 and a high of $290.40. Shares are currently priced at $282.91, which is +0.2% above the low and -2.6% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 7.94M, against a daily average of 7.77M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $290.40 and a 52-week low of $193.55.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $290.40 and a 52-week low of $193.55.

JNJ News

CNBC 3h
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market - CNBC

...

Jim Cramer says J&J is a 'metaphor for what's working' in the stock market - CNBC
Benzinga 5h
Johnson & Johnson Inks $2.2B Deal for Eye Drug Developer Ollin Biosciences

Johnson & Johnson (NYSE:JNJ) on Monday agreed to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company focused on therapies for serious eye dise...

Johnson & Johnson Inks $2.2B Deal for Eye Drug Developer Ollin Biosciences
24/7 Wall St. 6h
Treasury Yields Just Hit 4.88%, Changing the Math for Dividend Investors

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Treasury Yields Just Hit 4.88%, Changing the Math for Dividend Investors

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
25.9%
Sell
7.4%

More JNJ News

The Wall Street Journal 7h
Johnson & Johnson to Buy Eye-Disease Biotech Ollin

Ollin’s main experimental drug is designed to treat eye diseases that can cause vision loss. The purchase marks an expansion into eye medicines for J&J, which a...

Johnson & Johnson to Buy Eye-Disease Biotech Ollin
TipRanks 8h
Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & Johnson

Innovent Biologics ( (HK:1801) ) has issued an update. Innovent Biologics said its partner Ollin Biosciences entered a definitive agreement to be acquired by J...

TipRanks 8h
Blackstone Life Sciences announces $750M R&D funding agreement

Blackstone (BX) announced that funds managed by Blackstone Life Sciences will provide $750M in development funding to Johnson & Johnson (JNJ) to support the Pha...

The Wall Street Journal 9h
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

The deal adds OLN324, an investigational bispecific antibody for retinal vascular diseases. Reuters Johnson & Johnson JNJ 0.79 %increase; up pointing triangle...

Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
TipRanks 11h
M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights

Shares in U.S. medical giant Johnson & Johnson (JNJ) were higher in pre-market trading today on reports that it has set its sights on buying eye disease biotech...

Seeking Alpha 17h
J&J in discussions to buy Ollin Biosciences for up to $3.4B - report

J&J in discussions to buy Ollin Biosciences for up to $3.4B - report Nov 16, 2026, 12:21 AM ET Johnson & Johnson (JNJ) Stock By : Manshi Mamtora, CFA Johnson &...

J&J in discussions to buy Ollin Biosciences for up to $3.4B - report
Simply Wall St 3d
Johnson & Johnson Backs Prostate Cancer Device Development

Johnson & Johnson (NYSE: JNJ) agreed to invest in Francis Medical to support development of the Vanquish prostate cancer ablation device. The Vanquish system i...

Johnson & Johnson Backs Prostate Cancer Device Development

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.